Boston-based Dana-Farber Cancer Institute (DFCI), an affiliate of Harvard Medical School, acknowledged on Jan. 23 that it would seek retractions for six research papers and corrections for an additional 31.
The retractions and corrections come after Sholto David, a British molecular biologist, called out many of DFCI’s top brass, including CEO Dr. Laurie Glimcher and Chief Operating Officer Dr. William Hahn, alleging they had published papers that duplicated or manipulated data.
